Loading...
•
Dec 31, 2022
NeoGenomics Q4 2022 Earnings Report
NeoGenomics' organizational changes began to show results, capping off the year with sequential improvements in revenue, gross margin, and adjusted EBITDA.
Key Takeaways
NeoGenomics reported a 10% increase in fourth-quarter consolidated revenue, reaching $139 million. The company saw improvements in gross margin and adjusted EBITDA. Clinical Services revenue increased by 4% to $108 million, while Pharma Services revenue increased by 41% to $31 million.
Consolidated revenue increased by 10% to $139 million.
Clinical Services revenue increased by 4% to $108 million.
Pharma Services revenue increased by 41% to $31 million.
Consolidated gross profit increased 26% to $56.8 million.
Forward Guidance
The Company also issued 2023 guidance(3) today (in millions).
Positive Outlook
- Consolidated revenue increase
- Net loss decrease
- Adjusted EBITDA increase
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...